The positive preliminary Q4 revenue report suggests that Axsome Therapeutics is performing better than the market expected, which typically leads to an increase in investor confidence and a rise in stock price. Given that revenue is a key indicator of a company's financial health, this news is directly relevant and important to investors, and there is high confidence in the short-term positive impact on the stock.